Cryoport, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cryoport, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $176.18M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $156.77M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $168.66M | Mar 5, 2026 |
| FY2022 | Dec 31, 2022 | $60.36M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $60.46M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $64.15M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $52.30M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $56.44M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $56.69M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $56.19M | Feb 28, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $176.18M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $156.77M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $168.66M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $237.28M | Mar 7, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.32M | Mar 8, 2018 |
| FY2017 | Sep 30, 2017 | $3.00M | Mar 8, 2018 |
| FY2017 | Jun 30, 2017 | $2.92M | Mar 8, 2018 |
| FY2017 | Mar 31, 2017 | $2.71M | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $2.23M | Mar 8, 2018 |
| FY2017 | Sep 30, 2016 | $1.98M | Mar 8, 2018 |
| FY2017 | Jun 30, 2016 | $1.92M | Mar 8, 2018 |
| FY2017 | Mar 31, 2016 | $0 | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $1.46M | Jun 28, 2016 |
| FY2016 | Sep 30, 2015 | $1.44M | Jun 28, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.05M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $69.66M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $75.33M | Mar 5, 2026 |
| FY2022 | Dec 31, 2022 | $26.28M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $26.42M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $28.84M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $22.34M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $23.11M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $23.51M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $25.40M | Feb 28, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.30M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($114.76M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($99.59M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($37.33M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | ($275.53M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($32.69M) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | ($948.0K) | Mar 10, 2020 |
| FY2019 | Sep 30, 2019 | ($12.47M) | Mar 10, 2020 |
| FY2019 | Jun 30, 2019 | ($2.53M) | Mar 10, 2020 |
| FY2019 | Mar 31, 2019 | ($2.39M) | Mar 10, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.81M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($121.67M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($100.54M) | Mar 5, 2026 |
| FY2022 | Dec 31, 2022 | ($11.04M) | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | ($7.80M) | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | ($5.25M) | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | ($7.82M) | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | ($8.36M) | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | ($4.58M) | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | ($3.75M) | Feb 28, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.04M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $17.71M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $18.04M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $15.72M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $16.84M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $9.48M | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | $3.74M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $1.84M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $1.21M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $453.6K | Mar 8, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.82M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $109.81M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $108.26M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $120.06M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $97.56M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $56.86M | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | $31.29M | Feb 28, 2022 |
| FY2015 | Mar 31, 2015 | $6.41M | May 19, 2015 |
| FY2015 | Mar 31, 2014 | $5.11M | May 19, 2015 |
| FY2012 | Mar 31, 2013 | $1.4K | Jun 25, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.58M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($16.32M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($757.0K) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($1.85M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $8.13M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($14.87M) | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | ($1.32M) | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | ($3.35M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($3.58M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($3.74M) | Mar 8, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.44M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $17.25M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $38.79M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $22.11M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $23.88M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $8.92M | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | $5.34M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $2.91M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $1.71M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $657.7K | Mar 8, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $764.99M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $703.49M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $957.74M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $1.04B | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $1.11B | Feb 28, 2023 |
| FY2020 | Dec 31, 2020 | $552.41M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $135.87M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $56.62M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $20.26M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $8.11M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $262.35M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $301.59M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $468.72M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $482.91M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $471.14M | Feb 28, 2023 |
| FY2020 | Dec 31, 2020 | $169.71M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $9.59M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $18.07M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $2.38M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $2.43M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $502.64M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $401.90M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $489.02M | Mar 5, 2026 |
| FY2025 | Dec 31, 2022 | $555.84M | Mar 5, 2026 |
| FY2024 | Dec 31, 2021 | $641.83M | Mar 7, 2025 |
| FY2023 | Dec 31, 2020 | $382.70M | Mar 13, 2024 |
| FY2020 | Dec 31, 2019 | $126.28M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $38.55M | Mar 10, 2020 |
| FY2019 | Dec 31, 2017 | $17.89M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $5.68M | Mar 13, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.40M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $20.57M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $76.39M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $151.12M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $146.95M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $145.28M | Feb 28, 2023 |
| FY2020 | Dec 31, 2019 | $11.00M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $0 | Mar 10, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($688.88M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($757.18M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($642.42M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($542.83M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($467.54M) | Feb 28, 2023 |
| FY2020 | Dec 31, 2020 | ($192.01M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($159.32M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($140.99M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($131.43M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($123.53M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $250.49M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $34.14M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $35.19M | Mar 5, 2026 |
| FY2025 | Dec 31, 2022 | $29.23M | Mar 5, 2026 |
| FY2022 | Dec 31, 2021 | $139.10M | Feb 28, 2023 |
| FY2020 | Dec 31, 2020 | $36.87M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $47.24M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $37.33M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $15.04M | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | $4.52M | Mar 13, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Mar 31, 2013 | $1.29M | Jun 25, 2013 |
| FY2012 | Mar 31, 2012 | $325.3K | Jun 25, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 5, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | (5) | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 5, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | (5) | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Feb 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.85M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 49.91M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 48.97M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 48.33M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 49.62M | Feb 28, 2023 |
| FY2020 | Dec 31, 2020 | 39.84M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 37.34M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 30.32M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 25.70M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 17.60M | Mar 8, 2018 |